Abstract
Aim of this phase IIa hybrid study was to identify the optimal dose of mannan-conjugated birch pollen allergoids (T502) for the short-course treatment of birch-pollen induced allergic rhinoconjunctivitis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
